What is CNTX (CNTX) stock price today?

CNTX (CNTX) is currently trading at $0.62, up 4.47% today.

What is CNTX P/E ratio?

CNTX's P/E ratio is -6.84. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CNTX return on equity (ROE)?

CNTX's return on equity (ROE) is -60.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CNTX's market cap?

CNTX has a market capitalization of $56.69M.

NASDAQ · Biotechnology

CNTX (CNTX) Stock

$0.62 +4.47% NASDAQ: CNTX Healthcare

Valuation

Metric	Value
Price	$0.62
Market Cap	$56.69M
P/E Ratio	-6.84
P/B Ratio	3.98
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$3.62
52-Week Low	$0.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-60.00%
ROA	-52.94%
ROCE	-66.67%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	8.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-11.0M	$-15.0M	$-25.0M	$-30.0M	$-40.0M
Net Profit	$-10.0M	$-15.0M	$-24.0M	$-27.0M	$-36.0M
EPS	$-3.69	$-0.93	$-1.50	$-0.46	$-0.38
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$51.0M	$38.0M	$16.0M	$98.0M	$68.0M
Total Liabilities	$3.0M	$3.0M	$4.0M	$3.0M	$8.0M
Cash	$50.0M	$35.0M	$14.0M	$94.0M	$66.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026 Context Therapeutics Joins Russell 2000, Russell 3000 Indexes MT Newswires · Jul 6, 2026 Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes GlobeNewswire · Jul 6, 2026 Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish Insider Monkey · Jul 5, 2026 CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip Stocktwits · Jun 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-9.0M	$-14.0M	$-21.0M	$-15.0M	$-26.0M
Investing Cash Flow	$0	$-1.0M	$0	$-30.0M	$-2.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$49.0M	$-14.0M	$-21.0M	$80.0M	$-28.0M
Free Cash Flow	$-9.0M	$-14.0M	$-21.0M	$-29.0M	$-26.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-13.74%
Quick Ratio	8.96
Interest Coverage	—
Return 1Y	-15.48%
Return 3Y	-48.23%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLNNClene Inc.	$5.29	-1.86%	-1.66	$54.53M	0.00%
CNTB	$2.07	-1.67%	-2.31	$130.02M	0.00%
IFRX	$1.84	+6.98%	-4.16	$132.91M	0.00%
IMA	$5.69	+1.07%	-1.49	$64.18M	0.00%
KLRS	$3.40	+1.80%	-2.86	$63.59M	0.00%

About CNTX

CNTX is led by CEO Martin A. Lehr, employs 12 people, headquartered in US, publicly traded since 2021.

CNTX stock trades at $0.62 with a market capitalization of $56.69M. The stock is valued at a price-to-earnings (P/E) ratio of -6.84, price-to-book of 3.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.55 and $3.62, and currently trades 82.9% below its 52-week high.

On profitability, CNTX generates a return on equity (ROE) of -60.00%, return on capital employed of -66.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides